Clinical trials
Recurrence clinical trials
Below are recruiting recurrence clinical trials, each written for real people, not researchers. We’re tracking 1,423 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05772390RecruitingPhase 2
Second radiation for a small breast cancer return
This Phase 2 study tests whether giving targeted radiation again to the same breast can control a small, local breast cancer that came back after prior whole-breast radiation. It may help some patients avoid or delay further treatment for the breast while carefully checking safety.
Meldola, Forlì CesenaAges 18 years+ - NCT05832827RecruitingPhase 2
First treatment combo for thymic cancer using pembrolizumab plus drugs
This Phase 2 study tests a first (initial) treatment combination of pembrolizumab with three other drugs (carboplatin, paclitaxel, and lenvatinib) for advanced or recurrent thymic carcinoma. It aims to shrink tumors and improve control of the cancer when standard chemotherapy has not yet been tried for your situation.
Chūō, TokyoAges 18 years+ - NCT05838066RecruitingPhase 3
KN026 plus HB1801 for HER2-positive advanced breast cancer
This Phase 3 study tests whether taking KN026 with HB1801 as first treatment works better and is safe for people with HER2-positive breast cancer that has come back or spread. It may help by improving tumor response and delaying progression compared with the study’s treatment plan.
Beijing, chaoyangAges 18 years+ - NCT05874921Recruiting
Registry for adults with UTUC treated with Jelmyto
This registry collects information about adults with upper tract urothelial cancer (UTUC) who received Jelmyto after it was approved. It helps doctors understand outcomes and real-world experience with Jelmyto.
Santa Monica, CaliforniaAges 18 years+ - NCT05903833RecruitingPhase 2
Study pembrolizumab and lenvatinib for advanced vulvar cancer
This trial tests whether combining pembrolizumab with lenvatinib can shrink and control advanced vulvar squamous cell cancer that can’t be fully treated with surgery or strong radiation. It may help some people live longer and better control symptoms, but it also requires close monitoring and specific health criteria.
AugsburgAges 18 years+ - NCT05989178Recruiting
Recurrent Pregnancy Loss Registry
This study is a registry for people who have had repeated pregnancy losses. It will collect information to better understand and help manage this condition.
Vancouver, British ColumbiaAges 15–49 - NCT05997017RecruitingPhase 2
Nab-sirolimus plus letrozole for advanced endometrial cancer
This trial tests a combination of two drugs—nab-sirolimus and letrozole—for people with advanced or returning endometrioid endometrial cancer. The goal is to see if this combination can shrink tumors or slow cancer growth.
Little Rock, ArkansasAges 18 years+ - NCT06005103Recruiting
Testing a headband that sends brain pulses for depression
This study tests a new headband that sends gentle electrical pulses to the brain (T-PEMF) to lift depression. You might join if you have moderate to severe depression and don't have certain other conditions or implants.
Frederiksberg, Capital RegionAges 18–65 - NCT06022029RecruitingPhase 1
Study of injected ONM-501 alone or with cemiplimab for advanced cancers
This trial tests an injected study drug (ONM-501) alone or with another drug (cemiplimab) for people with advanced solid tumors or lymphomas that haven't responded to other treatments. It aims to find a safe dose and see if the combination helps shrink or control the cancer.
Los Angeles, CaliforniaAges 18 years+ - NCT06029270RecruitingPhase 2
Adding relatlimab to standard immunotherapy for nasopharyngeal cancer
This trial tests whether adding a new drug called relatlimab to the usual immunotherapy (nivolumab) helps people with nasopharyngeal cancer that has returned or spread. You will get standard chemotherapy plus nivolumab first, then if it works, you may be randomly assigned to get nivolumab alone or with relatlimab.
Dublin, CaliforniaAges 18 years+ - NCT06039709RecruitingPhase 1
Sound wave therapy for recurrent glioblastoma
This trial tests a new treatment called sonodynamic therapy that uses sound waves and a special drug to target brain tumors that have come back. It aims to see if this approach is safe and can shrink tumors in people who are eligible for surgery.
Charlottesville, VirginiaAges 18–80 - NCT06050148RecruitingPhase 2/Phase 3
Fecal Transplant to Prevent Repeat Urinary Tract Infections
This trial tests whether a fecal microbiota transplant (a procedure that transfers healthy bacteria from a donor's stool into your gut) can help prevent repeat urinary tract infections in women who have frequent infections.
HelsinkiAges 18–90 - NCT06064877RecruitingPhase 3
Study of ficlatuzumab plus cetuximab for advanced head and neck cancer
This trial tests a combination of two drugs, ficlatuzumab and cetuximab, for people with recurrent or metastatic head and neck cancer that is HPV-negative and has not responded to prior immunotherapy and chemotherapy. It aims to see if this combination can help shrink tumors or slow the disease.
Gilbert, ArizonaAges 18 years+ - NCT06069726RecruitingPhase 2
Testing atezolizumab for recurrent glioblastoma
This trial tests whether the immunotherapy drug atezolizumab can help people with glioblastoma that has come back after initial treatment. You will need to have a biopsy before starting the drug to confirm the tumor has returned.
San Francisco, CaliforniaAges 18 years+ - NCT06097975RecruitingPhase 1
Combined immunotherapy for recurrent glioblastoma
This trial combines two immunotherapy drugs (ipilimumab and nivolumab) given through a vein and directly into the brain for people with recurrent glioblastoma. The goal is to see if this approach can help control the tumor.
BrusselsAges 18 years+ - NCT06118086RecruitingPhase 1/Phase 2
Study of REM-422 for advanced adenoid cystic carcinoma
This trial tests an experimental drug called REM-422 for people with adenoid cystic carcinoma (ACC) that has spread, come back, or cannot be removed by surgery. The study has two parts: an early part for people with advanced ACC and a later part for those with a specific genetic change (MYB biomarker) in their tumor. The goal is to see if REM-422 can slow or stop cancer growth.
San Francisco, CaliforniaAges 18 years+ - NCT06157151RecruitingPhase 2
New drug plus pembrolizumab for advanced cervical cancer
This trial tests a new experimental drug, PRGN-2009, combined with the immunotherapy pembrolizumab (Keytruda) for people with HPV-related cervical cancer that has come back or spread. It is for those who have already tried pembrolizumab and are looking for another option.
Little Rock, ArkansasAges 18 years+ - NCT06161610Recruiting
Laser treatment for returning high-grade glioma
This study tests a laser ablation treatment for people whose high-grade glioma (a fast-growing brain tumor) has come back after standard therapy. The goal is to see if this minimally invasive laser procedure can help control the tumor.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06163092Recruiting
Antibiotics for chronic endometritis in recurrent miscarriage
This trial tests whether antibiotics can help women who have had two or more miscarriages in a row and may have a condition called chronic endometritis (inflammation in the lining of the uterus). If you have recurrent miscarriages and might have this inflammation, antibiotics could improve your chances of a successful pregnancy.
Hong KongAges 20–45 - NCT06168032Recruiting
COVID-19 vaccine for lung cancer patients
This trial is testing how well the COVID-19 vaccine works for people with lung cancer to prevent another infection. It also looks at certain biomarkers in your blood that might help predict your body's immune response.
BeijingAges 18 years+ - NCT06173349RecruitingPhase 1
New bladder therapy for BCG-resistant bladder cancer
This trial tests a new treatment for bladder cancer that does not respond to standard BCG therapy. The treatment uses tiny particles (micelles) that deliver a chemotherapy drug directly into the bladder, aiming to destroy cancer cells without needing surgery.
Sacramento, CaliforniaAges 18 years+ - NCT06181344Recruiting
Helping with fear of cancer returning after treatment
This program helps people who have finished treatment for breast, gynecological, or colorectal cancer manage fears about their cancer coming back. It offers screening and support to address those worries.
Hong KongAges 18 years+ - NCT06185621Recruiting
Aspirin to prevent recurrent pancreatitis
This trial tests if taking aspirin daily can prevent repeated attacks of acute pancreatitis. It's for people who have had at least two episodes of pancreatitis in the past year that were not caused by a medical procedure.
Xi'an, ShaanxiAges 14–80 - NCT06202248Recruiting
DaRT radiation therapy for prostate cancer that has returned
This trial tests a new type of radiation using tiny alpha-emitting seeds placed directly into the tumor. It is for people whose prostate cancer came back in the gland after initial treatment but hasn't spread elsewhere.
HaifaAges 18–120
Hear when a new Recurrence trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for recurrence?
- Yes. Clin2 currently lists 1,423 recruiting recurrence studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrence trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrence trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.